2010
Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease
Oyeku S, Green N, Pashankar F, Giardina P, Mullen C, Driscoll C. Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. Blood 2010, 116: 255. DOI: 10.1182/blood.v116.21.255.255.Peer-Reviewed Original ResearchSickle cell diseaseYears of ageEfficacy of hydroxyureaHU useUse of hydroxyureaMajority of providersCell diseaseSickle cell genotypeProvider barriersClinical indicationsHematology providersNIH Consensus Development ConferencePediatric sickle cell diseaseLong-term side effectsNational evidence-based guidelinesProvider levelBroader clinical indicationsChronic pain useAcute chest syndromePhase III trialsPatients ages 1Dose of hydroxyureaEvidence-based guidelinesOff-label useConsensus Development Conference
1997
Adverse Outcomes of Underuse of β-Blockers in Elderly Patients-Reply
Soumerai S, McLaughlin T, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse Outcomes of Underuse of β-Blockers in Elderly Patients-Reply. JAMA 1997, 277: 1436-1437. DOI: 10.1001/jama.1997.03540420032022.Peer-Reviewed Original ResearchCalcium channel blockersChannel blockersΒ-blockersNondihydropyridine calcium channel blockersNational evidence-based guidelinesDihydropyridine calcium channel blockerΒ-blocker useAdministrative claims databaseLipid-lowering agentsEvidence-based guidelinesEffective drug classClaims databaseAdverse outcomesDrug classesComparative efficacyBlockersCommunity settingsPatients' repliesAspirinPrevious reportsUnderuseOutcomesPatientsTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply